Alliance Global Partners initiated coverage of AcelRx Pharmaceuticals with a Buy rating and $4.25 price target. If approved, the analyst believes Niyad could take substantial share in the continuous renal replacement therapy market, where over 50% of patients can’t take standard Heparin and must rely on a “complicated” Citrate anti-coagulant or not use anything. The firm sees “multiple catalysts coming near term” for shares of AcelRx.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRX:
- AcelRx: FDA declined to issue EUA for Niyad at this time
- AcelRx price target lowered to $5 from $8 at H.C. Wainwright
- AcelRx upgraded to Buy from Neutral at H.C. Wainwright
- AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- ACRX Upcoming Earnings Report: What to Expect?
